IRIS

The rVSV-ZEBOV Ebolavirus vaccine confers protection within days after immunization, suggesting the contribution of innate immune responses. We report modulation of rVSV-ZEBOV vaccinee blood CD56+ NK cell numbers, NKG2D or NKp30 surface receptor expression, Killer Immunoglobulin-like Receptor (KIR)+ cell percentages and NK-cell-related genes on day 1 post immunization. Inverse correlations existed between the concentration of several plasma cytokines and inhibitory KIR+ CD56dim or cytokine-responsive CD56bright NK cells. Thus, NK cells may contribute to the early protective efficacy of rVSV-ZEBOV in humans. © 2020, The Author(s).

Pejoski, D., de Rham, C., Martinez-Murillo, P., Santoro, F., Auderset, F., Medaglini, D., et al. (2020). Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination. NPJ VACCINES, 5(1), 1-5 [10.1038/s41541-020-0179-4].

Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination

Santoro, Francesco;Medaglini, Donata;Pozzi, Gianni;Ciabattini, Annalisa
Membro del Collaboration Group
2020-01-01

Abstract

The rVSV-ZEBOV Ebolavirus vaccine confers protection within days after immunization, suggesting the contribution of innate immune responses. We report modulation of rVSV-ZEBOV vaccinee blood CD56+ NK cell numbers, NKG2D or NKp30 surface receptor expression, Killer Immunoglobulin-like Receptor (KIR)+ cell percentages and NK-cell-related genes on day 1 post immunization. Inverse correlations existed between the concentration of several plasma cytokines and inhibitory KIR+ CD56dim or cytokine-responsive CD56bright NK cells. Thus, NK cells may contribute to the early protective efficacy of rVSV-ZEBOV in humans. © 2020, The Author(s).
2020
NPJ VACCINES
Pejoski, D., de Rham, C., Martinez-Murillo, P., Santoro, F., Auderset, F., Medaglini, D., et al. (2020). Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination. NPJ VACCINES, 5(1), 1-5 [10.1038/s41541-020-0179-4].
1.1 Articolo in rivista
File in questo prodotto:
File Dimensione Formato  
s41541-020-0179-4.pdf

accesso aperto

Descrizione: Articolo
Tipologia: PDF editoriale
Licenza: Creative commons
Dimensione 3.5 MB
Formato Adobe PDF
Visualizza/Apri
3.5 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1107443